A CLEAR AND FOCUSED BUSINESS DEVELOPMENT STRATEGY
We are constantly seeking out new innovation opportunities through strategic partnerships, acquisitions and licenses. We strive to bolster our core therapeutic areas and expand into high-value adjacent therapeutic areas to create the most value for our patients, partners and Shire.
We are and will continue to strive to be the partner of choice for companies seeking to develop and commercialize innovative therapies for rare diseases.
Within the rare disease space, we have identified eight focus areas where we have existing or developing domain expertise.
*In these areas, we are also interested in non-orphan later stage opportunities (i.e., post proof of concept).
WHY PARTNER WITH SHIRE?
Our robust pipeline combined with our patient-centric, entrepreneurial culture and collaborative approach will be the engine of future innovation and development of the next generation of therapies. We have a history of successful collaborations and highly flexible deal structures with our partners. We remain committed to finding opportunities that can take our scientific savvy in small molecules and biologics and innovative work in rare diseases, neuroscience, gastrointestinal, hematology, immunology, oncology and ophthalmology to the next level. We are also interested in existing and emerging therapeutic technologies (e.g., small molecules, recombinant proteins, antibodies, gene therapies, gene editing). Shire’s global infrastructure makes us an agile partner, entrepreneurial in spirit and expert at collaboration. Through it all, we remain patient-focused, and absolutely committed to forging meaningful relationships with patient advocates and policy makers.
EXPLORE A PARTNERSHIP WITH SHIRE
To learn more about building a partnership with Shire, please contact us.
Licensing / Product Focused Acquisition